DE69824165D1 - Verwendung von chelerythrin und strahlung in der tumortherapie - Google Patents

Verwendung von chelerythrin und strahlung in der tumortherapie

Info

Publication number
DE69824165D1
DE69824165D1 DE69824165T DE69824165T DE69824165D1 DE 69824165 D1 DE69824165 D1 DE 69824165D1 DE 69824165 T DE69824165 T DE 69824165T DE 69824165 T DE69824165 T DE 69824165T DE 69824165 D1 DE69824165 D1 DE 69824165D1
Authority
DE
Germany
Prior art keywords
chelerythrin
radiation
tumor therapy
chelerythrine
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69824165T
Other languages
English (en)
Other versions
DE69824165T2 (de
Inventor
R Weichselbaum
Jose Quintans
J Chmura
W Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Arch Development Corp
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Publication of DE69824165D1 publication Critical patent/DE69824165D1/de
Application granted granted Critical
Publication of DE69824165T2 publication Critical patent/DE69824165T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69824165T 1997-03-25 1998-03-25 Verwendung von chelerythrin und strahlung in der tumortherapie Expired - Fee Related DE69824165T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US826814 1997-03-25
US08/826,814 US6025365A (en) 1997-03-25 1997-03-25 Chelerythrine and radiation combined tumor therapy
PCT/US1998/005842 WO1998042339A1 (en) 1997-03-25 1998-03-25 Use of chelerythrine and radiation for tumor therapy

Publications (2)

Publication Number Publication Date
DE69824165D1 true DE69824165D1 (de) 2004-07-01
DE69824165T2 DE69824165T2 (de) 2005-06-09

Family

ID=25247609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824165T Expired - Fee Related DE69824165T2 (de) 1997-03-25 1998-03-25 Verwendung von chelerythrin und strahlung in der tumortherapie

Country Status (12)

Country Link
US (1) US6025365A (de)
EP (1) EP0971710B1 (de)
JP (1) JP2001521552A (de)
CN (1) CN1172668C (de)
AT (1) ATE267599T1 (de)
AU (1) AU737613B2 (de)
CA (1) CA2284992A1 (de)
DE (1) DE69824165T2 (de)
DK (1) DK0971710T3 (de)
ES (1) ES2218814T3 (de)
PT (1) PT971710E (de)
WO (1) WO1998042339A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426351B1 (en) * 2000-08-11 2002-07-30 Dana-Farber Cancer, Inc. Chelerythrine-based therapies for cancer
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
WO2003013643A1 (en) * 2001-08-03 2003-02-20 Medrad, Inc. Immobilizer probe
AU2003264036A1 (en) * 2002-08-08 2004-03-03 Vanderbilt University Pi3k antagonists as radiosensitizers
JP2004284961A (ja) * 2003-03-19 2004-10-14 Okinawa Pref Gov 抗腫瘍成分をサルカケミカンから抽出した製剤、食品または食品添加物
CN1292750C (zh) * 2003-06-02 2007-01-03 张平 植物来源总生物碱组合物及其药物制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
KR100822887B1 (ko) 2006-10-12 2008-04-17 한국생명공학연구원 치매의 치료 또는 예방을 위한 조성물
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
CN102552264A (zh) * 2012-02-28 2012-07-11 苏州大学 血根碱在制备电离辐射防护剂中的应用
CN116407537A (zh) * 2023-03-03 2023-07-11 长春中医药大学 一种白屈菜红碱在制备用于治疗卵巢癌的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US433257A (en) * 1890-07-29 Salve
US209331A (en) * 1878-10-29 Improvement in medical compounds
US2344830A (en) * 1940-08-15 1944-03-21 Wisconsin Alumni Res Found Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal
US4145412A (en) * 1977-02-14 1979-03-20 Vipont Chemical Company Composition for application to oral cavity and method for preparation thereof
US4406881A (en) * 1980-05-20 1983-09-27 Vipont Laboratories Antimicrobial agent
US4376115A (en) * 1980-08-05 1983-03-08 Mccrorey Howard S Method and composition for treating teeth and method for preparing same
US4599228A (en) * 1981-01-19 1986-07-08 Vipont Laboratories, Inc. Antimicrobial agent
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
AU6714396A (en) * 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
HUP9601096A2 (hu) * 1996-04-26 1998-01-28 János Aradi Anti-HIV-aktivitással rendelkező gyógynövényalapú gyógyászati és gyógyhatású készítmény,és vegyületek

Also Published As

Publication number Publication date
JP2001521552A (ja) 2001-11-06
AU737613B2 (en) 2001-08-23
AU6869398A (en) 1998-10-20
ES2218814T3 (es) 2004-11-16
US6025365A (en) 2000-02-15
CN1255061A (zh) 2000-05-31
ATE267599T1 (de) 2004-06-15
EP0971710B1 (de) 2004-05-26
CA2284992A1 (en) 1998-10-01
DE69824165T2 (de) 2005-06-09
WO1998042339A1 (en) 1998-10-01
DK0971710T3 (da) 2004-09-27
PT971710E (pt) 2004-09-30
CN1172668C (zh) 2004-10-27
EP0971710A1 (de) 2000-01-19

Similar Documents

Publication Publication Date Title
GB2370746B (en) High definition radiation treatment with an intensity modulating multi-leaf collimator
DE69824165D1 (de) Verwendung von chelerythrin und strahlung in der tumortherapie
DK1173252T3 (da) Produkter og fremgangsmåder til brachyterapi
GB2361399B (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
ES8801546A1 (es) Un procedimiento para la preparacion de compuesto de 2,2-difluoronucleosidos.
NO983429D0 (no) Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering
DE69738918D1 (de) Lipoxinverbindungen und deren Verwendung zur Behandlung der Zellenwucherungsstörung
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
BR0115087A (pt) Membro radioativo para uso em braquiterapia e métodos de fazer um membro radioativo e de tratar uma condição que responda a terapia por radiação
AU587959B2 (en) The effect of human tumor necrosis factor and human interferon on human cancer cells and methods
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
ATE375795T1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE69202441D1 (de) Melatoninderivate und Kombinationen mit Antiestrogenen zur Behandlung von Brustkarzinoma.
ES484793A1 (es) Un aparato terapeutico de rayos de alta frecuencia
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
PL341151A1 (en) Substituted products of condensation of n-benzyl-3-indenylacetamides with heterocyclic aldehydes for use in treating neoplastic diseases
DE60030164D1 (de) 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ES2151508T3 (es) Empleo de inhibidores de reductasa 3-hidroxi-3-metilglutaril coenzima a como una modalidad en la terapia del cancer.
ATE285247T1 (de) Krebstherapie mit lymphotoxin
ES2187799T3 (es) Complejos de bis-platino con derivados de polimetileno como ligandos que tienen actividad antitumoral.
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
ATE92758T1 (de) Wirkstoff zur tumorbekaempfung.
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ARCH DEVELOPMENT CORP., CHICAGO, ILL., US

Owner name: DANA-FARBER CANCER INSTITUTE, INC., BOSTON, MASS.,

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee